-DOCSTART- -X- O
A -X- _ O
relative -X- _ O
immunosuppression -X- _ O
is -X- _ O
observed -X- _ O
in -X- _ O
patients -X- _ O
after -X- _ O
sepsis -X- _ B-Outcome
, -X- _ O
trauma -X- _ O
, -X- _ O
burns -X- _ O
, -X- _ O
or -X- _ O
any -X- _ O
severe -X- _ O
insults. -X- _ O
It -X- _ O
is -X- _ O
currently -X- _ O
proposed -X- _ O
that -X- _ O
selected -X- _ O
patients -X- _ O
will -X- _ O
benefit -X- _ O
from -X- _ O
treatment -X- _ O
aimed -X- _ O
at -X- _ O
boosting -X- _ O
their -X- _ O
immune -X- _ O
systems. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
host -X- _ O
immune -X- _ O
response -X- _ O
needs -X- _ O
to -X- _ O
be -X- _ O
considered -X- _ O
in -X- _ O
context -X- _ O
with -X- _ O
pathogen-type -X- _ O
, -X- _ O
timing -X- _ O
, -X- _ O
and -X- _ O
mainly -X- _ O
tissue -X- _ O
specificity. -X- _ O
Indeed -X- _ O
, -X- _ O
the -X- _ O
immune -X- _ O
status -X- _ O
of -X- _ O
leukocytes -X- _ O
is -X- _ O
not -X- _ O
universally -X- _ O
decreased -X- _ O
and -X- _ O
their -X- _ O
activated -X- _ O
status -X- _ O
in -X- _ O
tissues -X- _ O
contributes -X- _ O
to -X- _ O
organ -X- _ O
failure. -X- _ O
Accordingly -X- _ O
, -X- _ O
any -X- _ O
new -X- _ O
immune-stimulatory -X- _ O
therapeutic -X- _ O
intervention -X- _ O
should -X- _ O
take -X- _ O
into -X- _ O
consideration -X- _ O
potentially -X- _ O
deleterious -X- _ O
effects -X- _ O
in -X- _ O
some -X- _ O
situations -X- _ O
. -X- _ O

